Indoxyl Sulfate and Its Role in Chronic Kidney Disease
Author Information
Author(s): Muacevic Alexander, Adler John R, Kudo Akiko, Fukuda Akihiro, Gotoh Koro, Shibata Hirotaka
Primary Institution: Oita University
Hypothesis
The study aims to clarify the relationship between indoxyl sulfate (IS) and mineralocorticoid receptor (MR) activation in chronic kidney disease (CKD).
Conclusion
Indoxyl sulfate could enhance mineralocorticoid receptor transactivation in chronic kidney disease, suggesting that MR antagonists and antioxidants may help inhibit CKD progression.
Supporting Evidence
- Indoxyl sulfate levels were significantly increased in the 5/6 nephrectomy model.
- MR-mediated transcriptional activity was enhanced by indoxyl sulfate in COS-7 cells.
- Antioxidants like α-lipoic acid inhibited MR activation by indoxyl sulfate.
Takeaway
Indoxyl sulfate, a harmful substance in kidney disease, can make kidney problems worse by activating certain receptors, but using specific treatments might help protect the kidneys.
Methodology
The study used a 5/6 nephrectomy model in rats to assess MR activation and conducted in vitro experiments with COS-7 cells to evaluate MR transcriptional activity.
Limitations
The detailed molecular mechanisms of how IS increases MR protein levels remain to be elucidated, and the role of IS in other CKD models is still unclear.
Participant Demographics
Eight-week-old male Sprague-Dawley rats were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website